Nuveen’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.91B Sell
5,337,672
-96,900
-2% -$98.2M 1.33% 10
2025
Q4
$5.84B Buy
5,434,572
+17,796
+0.3% +$17M 1.53% 10
2025
Q3
$4.13B Sell
5,416,776
-272,957
-5% -$203M 1.09% 12
2025
Q2
$4.44B Buy
5,689,733
+103,274
+2% +$80.3M 1.23% 10
2025
Q1
$4.61B Buy
5,586,459
+383,064
+7% +$319M 1.4% 7
2024
Q4
$4.02B Buy
5,203,395
+135,889
+3% +$113M 1.13% 10
2024
Q3
$4.49B Sell
5,067,506
-87,877
-2% -$79M 1.26% 9
2024
Q2
$4.67B Sell
5,155,383
-129,843
-2% -$104M 1.36% 9
2024
Q1
$4.11B Sell
5,285,226
-78,720
-1% -$56M 1.22% 9
2023
Q4
$3.13B Buy
5,363,946
+89,168
+2% +$52M 1.01% 12
2023
Q3
$2.83B Buy
5,274,778
+174,753
+3% +$90M 1% 12
2023
Q2
$2.39B Sell
5,100,025
-59,378
-1% -$24.9M 0.83% 15
2023
Q1
$1.77B Buy
5,159,403
+123,239
+2% +$41.6M 0.66% 24
2022
Q4
$1.84B Sell
5,036,164
-98,034
-2% -$34.8M 0.71% 23
2022
Q3
$1.66B Sell
5,134,198
-44,141
-0.9% -$14M 0.67% 21
2022
Q2
$1.68B Buy
5,178,339
+99,705
+2% +$29.9M 0.65% 22
2022
Q1
$1.47B Buy
5,078,634
+636,694
+14% +$164M 0.48% 36
2021
Q4
$1.23B Sell
4,441,940
-135,923
-3% -$34.5M 0.36% 49
2021
Q3
$1.06B Sell
4,577,863
-507,035
-10% -$125M 0.33% 57
2021
Q2
$1.17B Sell
5,084,898
-249,534
-5% -$50.1M 0.35% 49
2021
Q1
$997M Sell
5,334,432
-1,198,133
-18% -$234M 0.32% 61
2020
Q4
$1.1B Sell
6,532,565
-1,330,664
-17% -$199M 0.37% 51
2020
Q3
$1.16B Sell
7,863,229
-163,638
-2% -$25.3M 0.45% 44
2020
Q2
$1.32B Buy
8,026,867
+2,372,251
+42% +$364M 0.54% 27
2020
Q1
$784M Buy
5,654,616
+1,533,024
+37% +$211M 0.38% 54
2019
Q4
$542M Sell
4,121,592
-2,740,499
-40% -$318M 0.21% 106
2019
Q3
$767M Sell
6,862,091
-403,753
-6% -$45M 0.31% 62
2019
Q2
$805M Buy
7,265,844
+7,229,751
+20,031% +$851M 0.32% 57
2019
Q1
$4.68M Sell
36,093
-321
-0.9% -$39K 0.03% 517
2018
Q4
$4.21M Sell
36,414
-294
-0.8% -$32.8K 0.03% 510
2018
Q3
$3.94M Sell
36,708
-719
-2% -$71.9K 0.02% 541
2018
Q2
$3.19M Buy
37,427
+285
+0.8% +$23.4K 0.02% 538
2018
Q1
$2.87M Sell
37,142
-14
-0% -$1.13K 0.02% 552
2017
Q4
$3.14M Sell
37,156
-329
-0.9% -$28K 0.02% 525
2017
Q3
$3.21M Buy
37,485
+63
+0.2% +$5.17K 0.02% 545
2017
Q2
$3.08M Sell
37,422
-25,416
-40% -$2.07M 0.02% 547
2017
Q1
$5.29M Sell
62,838
-100,323
-61% -$8.04M 0.03% 512
2016
Q4
$12M Buy
163,161
+87,572
+116% +$6.52M 0.06% 400
2016
Q3
$6.07M Hold
75,589
0.04% 497
2016
Q2
$5.95M Sell
75,589
-8,564
-10% -$645K 0.04% 459
2016
Q1
$6.06K Buy
84,153
+3,348
+4% +$253K 0.03% 437
2015
Q4
$6.81K Sell
80,805
-2,691
-3% -$223K 0.04% 408
2015
Q3
$6.99K Buy
83,496
+1,625
+2% +$137K 0.04% 407
2015
Q2
$6.83K Sell
81,871
-385
-0.5% -$29.3K 0.04% 459
2015
Q1
$5.98M Buy
82,256
+375
+0.5% +$26.7K 0.03% 483
2014
Q4
$5.65M Buy
81,881
+16,752
+26% +$1.13M 0.03% 516
2014
Q3
$4.22M Sell
65,129
-17,264
-21% -$1.09M 0.03% 592
2014
Q2
$5.12M Sell
82,393
-6,177
-7% -$369K 0.03% 551
2014
Q1
$5.21M Sell
88,570
-1,468
-2% -$81.9K 0.03% 525
2013
Q4
$4.59M Sell
90,038
-110,535
-55% -$5.54M 0.03% 535
2013
Q3
$10.1M Buy
200,573
+634
+0.3% +$33.2K 0.07% 365
2013
Q2
$9.82M Buy
+199,939
New +$10.9M 0.07% 353

Other funds holding LLY

Nuveen's LLY Position: Q1 2026 in Review

Nuveen reduced its Eli Lilly (LLY) stake by 1.8% in Q1 2026, selling an estimated $98.2M and leaving 5,337,672 shares worth $4.91B. The position accounts for 1.33% of the portfolio, ranked #10.

Nuveen first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.84B in Q4 2025. 4,360 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Nuveen held 5,337,672 shares of Eli Lilly worth $4.91B as of Q1 2026.
  • Nuveen sold 96,900 Eli Lilly shares in Q1 2026, an estimated $98.2M.
  • Eli Lilly made up 1.33% of Nuveen's portfolio in Q1 2026, its #10 holding.
  • Nuveen first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Nuveen's Eli Lilly position peaked at $5.84B in Q4 2025.
  • 4,360 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.